By allowing the company to run all production lines simultaneously, the project will expand the number of suites from five to nine, significantly boosting production of cell banks for vaccines, therapeutic antibodies and gene therapies. The investment will also quadruple capacity for biosafety tests, allowing Clean Cells to meet increased demand from both existing and new clients.

“The production of cell banks for vaccines and therapeutic antibodies has known a strong upward trend over the past two years. We’ve hit the maximum capacity in our laboratories to offer our clients the most optimal services, which is exactly why we are almost doubling the number of production suites,” said Olivier Boisteau, co-founder and strategic adviser at Clean Biologics, Clean Cells parent group.

Laporte Euro, a specialist in designing and constructing pharmaceutical laboratories, and French engineering and consultation company Otéis are supporting Clean Cells on the project.

Clean Cells employs 112 staff and provides R&D, production and quality control testing services to the biopharmaceutical industry. At its two-part site in western France, the CDMO has several manufacturing laboratories and analytical areas for developing bespoke assays and performing GMP testing. Its sister company Naobios is a CDMO focused on developing and manufacturing virus-based products.

Author: Elaine Burridge, Freelance Journalist